Journal
HUMAN VACCINES & IMMUNOTHERAPEUTICS
Volume 16, Issue 12, Pages 2963-2972Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/21645515.2020.1808410
Keywords
COVID-19; SARS-CoV-2; immunotherapeutics; convalescent plasma therapy; hyperimmune immunoglobulin; SARS; MERS
Categories
Ask authors/readers for more resources
Passive immunotherapeutics (PITs), including convalescent plasma, serum, or hyperimmune immunoglobulin, have been of clinical importance during sudden outbreaks since the early twentieth century for the treatment of viral diseases such as severe acute respiratory syndrome (SARS), middle east respiratory syndrome (MERS) and swine flu (H1N1). With the recent SARS-CoV-2 pandemic, wherein effective antivirals and vaccines are still lacking, an interest in convalescent plasma therapy as a lifesaving option has resurfaced due to its capacity for antigenic neutralization and reducing viremia. This review summarizes convalescent blood products (CBPs) in terms of current technologies and the shortcomings related to the collection, manufacture, pathogen inactivation, and banking of CBPs, with a specific focus on their plausible applications, benefits, and risks in the COVID-19 pandemic.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available